These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 18564012)

  • 21. Evaluation of interferences between dengue vaccine serotypes in a monkey model.
    Guy B; Barban V; Mantel N; Aguirre M; Gulia S; Pontvianne J; Jourdier TM; Ramirez L; Gregoire V; Charnay C; Burdin N; Dumas R; Lang J
    Am J Trop Med Hyg; 2009 Feb; 80(2):302-11. PubMed ID: 19190230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. "Guidelines for the clinical evaluation of dengue vaccines in endemic areas": summary of a World Health Organization Technical Consultation.
    Edelman R; Hombach J
    Vaccine; 2008 Aug; 26(33):4113-9. PubMed ID: 18597906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dengue fever in international travelers.
    Jelinek T
    Clin Infect Dis; 2000 Jul; 31(1):144-7. PubMed ID: 10913412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk estimates of dengue in travelers to dengue endemic areas using mathematical models.
    Massad E; Wilder-Smith A
    J Travel Med; 2009; 16(3):191-3. PubMed ID: 19538580
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dengue surveillance in preparation for field vaccine trials.
    Letson GW
    J Clin Virol; 2009 Oct; 46 Suppl 2():S10-2. PubMed ID: 19800559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines.
    Brandler S; Tangy F
    Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):271-91. PubMed ID: 17869338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children.
    Simasathien S; Thomas SJ; Watanaveeradej V; Nisalak A; Barberousse C; Innis BL; Sun W; Putnak JR; Eckels KH; Hutagalung Y; Gibbons RV; Zhang C; De La Barrera R; Jarman RG; Chawachalasai W; Mammen MP
    Am J Trop Med Hyg; 2008 Mar; 78(3):426-33. PubMed ID: 18337339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The first licensed dengue vaccine: can it be used in travelers?
    Wilder-Smith A
    Curr Opin Infect Dis; 2019 Oct; 32(5):394-400. PubMed ID: 31305495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dengue vaccine: opportunities and challenges.
    Hatch S; Mathew A; Rothman A
    IDrugs; 2008 Jan; 11(1):42-5. PubMed ID: 18175262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccination of travelers: how far have we come and where are we going?
    Chen LH; Hill DR; Wilder-Smith A
    Expert Rev Vaccines; 2011 Nov; 10(11):1609-20. PubMed ID: 22043959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes.
    Ramanathan MP; Kuo YC; Selling BH; Li Q; Sardesai NY; Kim JJ; Weiner DB
    Vaccine; 2009 Oct; 27(46):6444-53. PubMed ID: 19580892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Severe dengue virus infection in travelers: risk factors and laboratory indicators.
    Wichmann O; Gascon J; Schunk M; Puente S; Siikamaki H; Gjørup I; Lopez-Velez R; Clerinx J; Peyerl-Hoffmann G; Sundøy A; Genton B; Kern P; Calleri G; de Górgolas M; Mühlberger N; Jelinek T;
    J Infect Dis; 2007 Apr; 195(8):1089-96. PubMed ID: 17357044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Travelers' vaccines].
    Ouchi K
    Nihon Rinsho; 2011 Sep; 69(9):1599-603. PubMed ID: 21922760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Future prospects in developing of dengue vaccines].
    Valero N; Levy A
    Invest Clin; 2008 Jun; 49(2):135-8. PubMed ID: 18717261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of a live attenuated tetravalent candidate dengue vaccine in naïve and previously infected cynomolgus macaques.
    Koraka P; Benton S; van Amerongen G; Stittelaar KJ; Osterhaus AD
    Vaccine; 2007 Jul; 25(29):5409-16. PubMed ID: 17560694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru.
    Lanata CF; Andrade T; Gil AI; Terrones C; Valladolid O; Zambrano B; Saville M; Crevat D
    Vaccine; 2012 Sep; 30(41):5935-41. PubMed ID: 22863660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Towards a dengue vaccine: progress to date and remaining challenges.
    Guy B; Almond JW
    Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):239-52. PubMed ID: 17889365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent progress on sanofi pasteur's dengue vaccine candidate.
    Lang J
    J Clin Virol; 2009 Oct; 46 Suppl 2():S20-4. PubMed ID: 19800562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-benefit of WC/rBS oral cholera vaccine for vaccination against ETEC-caused travelers' diarrhea.
    Lundkvist J; Steffen R; Jönsson B
    J Travel Med; 2009; 16(1):28-34. PubMed ID: 19192125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Japanese encephalitis in a U.S. traveler returning from Thailand, 2004.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2005 Feb; 54(5):123-5. PubMed ID: 15703694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.